Epidermal Growth Factor Receptor and Glypican-3 in Hepatocellular Nodules: A Clinicopathologic Study
LE Kernochan, J Alexander, PE Swanson, MM Yeh. Univ. of Washington, Seattle
Background: Epidermal growth factor receptor (EGFR) is overexpressed in hepatocellular carcinoma (HCC) and is a potential therapeutic target, but correlation between EGFR and clinicopathologic attributes of HCC including clinical outcome is controversial and correlation between EGFR and the novel HCC selective marker Glypican-3 (GP3) is lacking. We herein examined the expression of these markers in HCC and other diagnostically challenging, mimicking lesions including high grade dysplastic nodule (HGDN) and hepatocytic adenoma (HCA), and the correlation between GP3 and EGFR in HCC with correlation to survival.
Design: Formalin-fixed sections of 59 HCC, 8 HGDN, and 17 HCA were stained with antibodies to EGFR and GP3. The results were scored for intensity (none, weak, moderate, strong) and distribution (none, <10%, 10-33%, 34-66%, 67-100%) in lesional and non-lesional cells. The results were compared with differentiation (well, moderate or poor), Edmonson-Steiner (ES) nuclear grade (1-4) and survival in HCC.
Results: GP3 and EGFR were very sensitive for HCC, but GP3 was more specific in separating HCC from cirrhotic liver, HGDN, and HCA: